Immuron (IMRN) Cash from Investing Activities (2016 - 2024)
Immuron (IMRN) recorded quarterly Cash from Investing Activities of $35309.1 in Q4 2024, down 64.67% quarter-over-quarter from $99932.2 in Q4 2023, and down 64.67% on a YoY basis from $99932.2 in Q1 2024.
Immuron (IMRN) Cash from Investing Activities (2016 - 2024) Analysis & Trends
Immuron's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $35309.1 for Q4 2024.
- In Q4 2024, Cash from Investing Activities fell 64.67% year-over-year to $35309.1; the TTM figure through Dec 2024 stood at -$2.5 million (up 1.43% YoY), while the FY2025 annual figure was -$2.9 million, down 985.46% from the prior year.
- Cash from Investing Activities was $35309.1 for Q4 2024 at Immuron, down from $99932.2 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $99932.2 in Q4 2023 to a low of -$2.6 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$492615.7 across 5 years, with a median of $5550.2 in 2021.
- The sharpest annual moves came in 2021 and 2022: Cash from Investing Activities soared 1943.91% in 2021, then slumped 47009.79% in 2022.
- A 5-year view of Cash from Investing Activities shows it stood at -$301.0 in 2020, then jumped by 1943.91% to $5550.2 in 2021, then plunged by 47009.79% to -$2.6 million in 2022, then jumped by 103.84% to $99932.2 in 2023, then slumped by 64.67% to $35309.1 in 2024.
- The last three Cash from Investing Activities figures came in at $35309.1 (Q4 2024), $99932.2 (Q4 2023), and -$2.6 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2021 | 5,550.16 |
| Dec 31, 2021 | 5,550.16 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2016 | 1,416.72 |
| Dec 31, 2016 | 1,416.72 |